Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
about
History of clinical transplantationCyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbitsThe mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotectionThe mitochondrial permeability transition from yeast to mammalsCyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complexOxazolone-induced delayed type hypersensitivity reaction in the adult yucatan pigs. A useful model for drug development and validationCyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.Liver transplantation--the first 25 years.Liver transplantation, 1980, with particular reference to cyclosporin-A.Effect of cyclosporin A on murine natural killer cells.Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents.Cyclosporin A enhances neural precursor cell survival in mice through a calcineurin-independent pathwayCurrent status of hepatic transplantation.Isohemagglutinins of graft origin after ABO-unmatched liver transplantation.Evolution of liver transplantation.Past and future prospects of orthoptic liver transplantation.Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factorsCyclosporin A: a powerful immunosuppressantLack of effect of spiramycin on cyclosporin pharmacokineticsSteps in immunosuppression for renal transplantation.In vitro effect of cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis.Liver and kidney transplantation in children receiving cyclosporin A and steroids.Fifteen years of clinical liver transplantation.Cyclosporin A-treated guinea pig responder cells secrete a genetically restricted factor that suppresses the mixed leukocyte reaction.Activation of antigen-specific suppressor T cells in the presence of cyclosporin requires interactions between T cells of inducer and suppressor lineageStage-selective inhibition of rodent malaria by cyclosporine.Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patientsCyclosporin A inhibits Coccidioides immitis in vitro and in vivo.Vascular effects of cyclosporine A in vivo and in vitro.Thymic and lymphoid changes and serum immunoglobulin abnormalities in mice receiving cyclosporine.Prevention of diabetes mellitus in the BB/W rat with Cyclosporin-AEffect of host immune status on the spontaneous metastasis of cloned cell lines of the 13762NF rat mammary adenocarcinoma.Severe systemic vascular necrosis in cyclosporin-treated rabbits with acute serum sicknessThe Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology.Recent advances in the treatment of graft-versus-host disease.Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitroSelective suppression of an early step in human B cell activation by cyclosporin A.Paradoxical effects of cyclosporin A on collagen arthritis in rats.Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cellsCyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats.
P2860
Q24596303-FB668D9F-A520-45A1-A09C-7870401DA8BEQ24645745-865B4BA0-CF5F-4202-A4D7-A98AE04A6E03Q28248925-EC741DB2-54A7-433A-A021-9B01D9E78657Q28279895-C70C533D-E5F9-4814-9D84-1313C3AFFB36Q28507223-DB9B3710-2022-4FBB-9151-500F624C542EQ30429819-EEE3C152-F35C-46FA-B96D-9933C7FF46D1Q33556926-A940867F-24EB-408D-84B1-796DEB9732F8Q33616157-D0358A63-FB9D-4D94-A45E-22EB083673A5Q33752966-9CD637ED-F267-4256-8794-6A488F761927Q33912886-3DD11261-7585-4450-97EC-5A5DF5EE167DQ33916202-C6717780-C454-4F38-BAA0-12FC26B9C516Q33935614-4520558B-0869-457A-BB6E-D7CFD3303680Q34207236-16841D9E-A894-4EA4-8994-BB231E04009BQ34240601-478D66F1-025B-45A7-974D-881F8CE7AA3FQ34275840-FD59807B-8AB0-4F2C-8DA0-B4AC5C3D8F00Q34275886-1BBDDB95-D4A0-4EC3-9245-893BC0E23A0FQ34275901-8B9A76B8-5C8E-4B43-B0DC-77BB9D620095Q34278064-E24C5CBF-0C0D-4064-BDC6-88BF7AAB36ABQ34397330-D5D426DB-F639-4B2C-9C5A-FDCF4541417EQ34497811-FD9A5F4D-3E44-45FD-8C3E-1407FF2ADFCDQ34529385-9E00FE4D-4979-43C5-93FC-207B9355A136Q34561587-CD75FB30-B926-4384-8B56-7E33AF118BEFQ34965480-E38F6DA9-9B94-44B4-AD59-86FD112C636CQ35202443-3856AF6E-7872-4A62-991F-47D87FAE45C2Q35208343-2AB0ECD5-AFF9-40B3-805C-AA4D678CDFFFQ35298344-DA781700-6AB3-4765-A05C-F08B28FC1B73Q35582940-927E0D21-B25D-4D0D-8A04-E1F12007322CQ35755731-C0F8A924-4451-4B48-8540-2ABF2914FDBEQ35811806-3F62A41A-3058-4752-AB1D-9436D54AE933Q35856501-27B3C455-83CC-4F53-B960-473A212A111FQ35858507-F4D2719F-038D-4332-8D65-AD2911E65A77Q35992617-2AE9EEF9-006F-46B2-8E60-E01DFAD771E0Q36090368-8674A688-8F62-4F02-9215-75F5367BDE8FQ36146320-101998AC-18D1-44AA-974E-A27667E59F82Q36148596-88681D3D-89F4-4E27-B977-7A83807DB3E8Q36333498-6F4758B5-FAA4-4FE6-A9DE-DB8C0F34F74CQ36348079-012CBCEE-006A-4CEA-BEB5-7CA418188F1EQ36348238-DD230ED8-295E-4E6A-B712-623266893626Q36351226-E3531651-A54E-4646-A9F9-A6FC53EAE487Q36353085-B4862641-C619-473E-B51B-5A0BF0EB9A26
P2860
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh
1977年學術文章
@zh-hant
name
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
@en
type
label
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
@en
prefLabel
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
@en
P2093
P1433
P1476
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
@en
P2093
P304
P577
1977-06-01T00:00:00Z